In a recent conversation with James Feliciano, former president of AbbVie Japan, we delved into the intricacies of leadership in the Japanese pharmaceutical industry. Feliciano, a seasoned industry veteran, shared valuable insights into his experiences, challenges, and successes.Navigating the Abbott…
HOME > BUSINESS
BUSINESS
- Favorable PIII Data Out for Nichi-Iko’s Remicade Biosimilar
June 23, 2015
- Biogen Idec Japan Rebranded as Biogen Japan
June 23, 2015
- Opdivo Wins European Approval for Advanced Malignant Melanoma: BMS
June 23, 2015
- Fycompa Approved as Adjunctive Treatment for Primary Generalized Tonic-Clonic Seizures in US: Eisai
June 23, 2015
- Japan Diabetes Market Grows 6.1% in FY2014: Survey
June 22, 2015
- Novartis Launches Exforge OD Tablets
June 22, 2015
- Daiichi Sankyo Initiates Multinational PIII Study of Edoxaban for Venous Thromboembolism in Cancer
June 22, 2015
- Japan to Participate in Asian PIII Trial of NC-6004 for Pancreatic Cancer: NanoCarrier
June 19, 2015
- 30 Companies Obtain Listing for Plavix Generics
June 19, 2015
- JCR, Sumitomo Dainippon Collaborate in Blood-Brain Barrier Penetration Technology for Drug Discovery
June 19, 2015
- Generic Market to Grow 9.4% in FY2015: Yano Research
June 18, 2015
- Japanese Generic Market to Reach 867.9 Billion Yen in FY2014: Survey
June 17, 2015
- Taiho Licenses Lonsurf to Servier of France for Europe
June 16, 2015
- Takeda to Submit Plans to Improve Business Operations after MHLW Order
June 15, 2015
- Lenvima More Beneficial to Patients against Sorafenib: Dr Tahara of National Cancer Center
June 15, 2015
- Carna Biosciences Licenses Its Kinase Inhibitor to Janssen Biotech of US
June 15, 2015
- Toujeo Shows Similar Glycemic Control to Lantus in PIII Study in Japanese Patients: Sanofi
June 12, 2015
- PeptiDream to Receive Milestone Payments from BMS for Designating Clinical Candidate Compound
June 12, 2015
- FY2014 Earnings of 24 Major Japanese Drug Makers: Jiho Tally
June 12, 2015
- NanoCarrier to Initiate PI Study of NC-6004 for Head, Neck Cancer in Japan
June 11, 2015
ページ
The Ministry of Health, Labor and Welfare (MHLW) on December 18 presented a proposal to define the scope of products…
Eli Lilly’s Kisunla (donanemab) will join the Japanese reimbursement list on November 20, with a health ministry panel giving the…
Will an “off-year” drug price revision happen in April 2025 or not? Over the last week, expectations have been up…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…